Compass Therapeutics Inc (CMPX)

Form 8-K - Current report

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs...

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a...

Form 8-K - Current report

Compass Therapeutics to Participate in Upcoming June Investor Events

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage...

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and...

Compass Therapeutics to Participate in Upcoming May Investor Events

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update 

As recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel...

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material